July 1, 2026 marks a historic turning point for the global novel tobacco industry!
The U.S. Food and Drug Administration (FDA) officially announced that it has granted Modified Risk Tobacco Product (MRTP) authorization to Swedish Match USA. A total of 20 ZYN nicotine pouch products have obtained the world’s first official harm-reduction qualification in the nicotine pouch category.
This milestone eliminates the traditional market-entry-only positioning of nicotine pouches. Following IQOS heated tobacco products and General snus, ZYN has become the third tobacco product globally endorsed by the FDA with official harm-reduction recognition, completely restructuring the regulatory and market landscape of the smoke-free alternative sector in the United States and worldwide.
Core Event: 20 Products Officially Authorized for Harm-Reduction Claims
All 20 authorized ZYN products completed the FDA Premarket Tobacco Product Application (PMTA) approval in January 2025, securing legal sales eligibility in the U.S. market. The product lineup covers 10 mainstream flavors, all available in two nicotine strengths: 3mg and 6mg.
Official FDA authorized harm-reduction statement:
Replacing cigarettes with ZYN may reduce the risk of oral cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
Official Boundary Clarification: This MRTP authorization is exclusive to the 20 specified ZYN products and does not represent full category approval. Any other brand seeking equivalent harm-reduction marketing qualifications must independently submit comprehensive scientific and clinical data for full FDA case-by-case review, with extremely high entry barriers.
Key Distinction: PMTA vs. MRTP — Basic Access vs. Top-Tier Endorsement
The two core FDA regulatory pathways differ drastically in value and entry standards, which are often confused by industry practitioners:
PMTA (Premarket Tobacco Product Application): Grants only legal market access. No harm-reduction or comparative low-risk marketing is permitted, serving merely as the basic industry entry threshold.
MRTP (Modified Risk Tobacco Product Authorization): The highest-level official endorsement in the tobacco industry with extremely rigorous review standards. Brands must verify three core criteria via extensive toxicological, clinical, and population tracking data: the product significantly reduces disease risks compared with combustible cigarettes; it does not initiate nicotine use among non-smokers and minors; and it delivers net public health benefits to the overall user population.
To date, no vaping products worldwide have obtained MRTP harm-reduction authorization, demonstrating the unparalleled credibility of ZYN’s latest approval.
Solid Scientific Data Backs the Rigorous Approval
The MRTP approval is supported by a complete, closed-loop scientific evidence chain, with authentic clinical data verifying ZYN’s cigarette substitution efficacy:
Over half of adult smokers successfully quit combustible cigarettes entirely within 30 days after switching to ZYN;
Among dual users, 80.7% reduced their cigarette consumption, while 57.2% cut their daily smoking volume by more than 50%.
The FDA has imposed strict long-term regulatory restrictions rather than unrestricted authorization: the MRTP license is valid for only 5 years, requiring full re-submission of monitoring data for renewal. Post-market continuous monitoring is mandatory to track user behavior, consumer perception, and youth exposure data. The FDA reserves the right to revoke the authorization at any time if a significant rise in youth usage is detected.
Official Public Health Reminder: No tobacco product is absolutely safe. Non-smokers and minors are strictly prohibited from nicotine exposure. MRTP status only indicates reduced risks relative to combustible cigarettes, not zero risk.
